Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma
| Autor: | Kwanza T Warren, Yang Liu, Kevin A. Walter, Margie Richardson, Michael T. Milano, Jennifer Serventi, Nimish Mohile, Myla Strawderman |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Newly diagnosed Disease-Free Survival Internal medicine Overall survival Temozolomide Medicine Humans Clinical efficacy Clinical care Survival rate Antineoplastic Agents Alkylating Aged Aged 80 and over Adult patients business.industry Proportional hazards model Brain Neoplasms General Medicine Middle Aged medicine.disease Combined Modality Therapy Dacarbazine Survival Rate Treatment Outcome Female business Glioblastoma |
| Zdroj: | Anticancer research. 40(10) |
| ISSN: | 1791-7530 |
| Popis: | Background/aim Whether adding tumor treating fields (TTF) to the Stupp protocol increases survival for glioblastoma (GBM) patients in routine clinical care remains unknown. Patients and methods We retrospectively identified adult patients with newly diagnosed GBM (n=104) treated with the Stupp protocol or TTF at our Institution. Results Thirty-six percent (37/104) of patients received TTF in conjunction with the Stupp protocol and these patients had increased 6-month (p=0.006) and 1-year (p=0.170), but not 2-year survival rates compared to the 67-patients who received Stupp alone. The improvement of survival rate at 6-month was further confirmed by a modified Poisson model (p=0.010). However, we did not observe any improvement in overall survival (OS) with a Cox model. Conclusion While adding TTF to the Stupp protocol appeared to benefit patients with newly diagnosed GBM, this effect was mild and may be largely due to selection bias. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|